via Medical Xpress
A holistic approach toward analyzing brain images improves the effectiveness of brain stimulation, with far-reaching benefits for neural therapeutics.
A new method of brain imaging analysis offers the potential to greatly improve the effectiveness of noninvasive brain stimulation treatment for Alzheimer’s, obsessive compulsive disorder, depression, and other conditions. Duke researchers developed the new method, which for the first time analyzed the whole brain network rather than a single region of the brain. This new method identified brain areas that exert the most control on network function. The study, published in The Journal of Neuroscience, has direct implications for improving the benefits of transcranial magnetic stimulation, which is currently used for major depression and obsessive compulsive disorder, and may soon lead to therapeutic treatment for memory disorders such as Alzheimer’s and dementia.
Researchers at the Duke Brain Stimulation Research Center (BSRC) developed a method of analysis that relies on the concept of controllability, a network principle that helps to predict how one area of the brain influences a whole network involved in regulating behavior. The authors measured controllability using functional magnetic resonance imaging (fMRI) to determine how much change TMS would induce as participants did a working memory task. In this task, individuals had to keep bits of information briefly in their memory and manipulate this information in their mind before answering questions about it. This task was used because of the importance of working memory in everyday life (like ordering your shopping list in your mind before walking through the grocery store) and because it is highly impacted by aging, particularly in conditions like Alzheimer’s and dementia.
“Essentially, we look at the brain not as a set of discrete islands, but as a dense web of connections that have lots of mutual influence,” said lead researcher Dr. Simon Davis, Assistant Professor of Neurology at Duke. “Controllability allows us a framework for identifying which nodes in this web are most likely to be influenced by brain stimulation, and for that reason likely to show plasticity and improvement after TMS treatments.”
The controllability measure, which is based on a static, structural image of the brain, was used to predict dynamic activity. “Brain activity is like the spatial pattern of traffic in a city. Although the traffic pattern is ever-changing, it is always confined by the topology of the road network,” said Lifu Deng, a Duke graduate student in the Department of Psychology and Neuroscience, and co-lead on the paper. “Controllability links the stimulation at one location to the global pattern of brain activity. In our study, for instance, this is the activation patterns signifying better working memory.”
Previously, there has not been a systematic way to identify which brain areas are the most likely to produce global chances, because most studies have focused on just one region. This study, however, advanced the field by considering the whole brain network.
While healthy adults participated in the study, the research likely has implications for memory disorders. “Memory dysfunction as a network phenomenon that relies on multiple brain regions operating under coordinated dynamics. The typical focus on the TMS response at a single site represents a fundamental limitation in the approach of neurostimulation therapies because it neglects global impairments in whole network that underlies memory dysfunction,” said Lysianne Beynel, a postdoctoral associate in the BSRC and first author on the study.
Ultimately, this non-invasive brain stimulation method will be used to promote healthy brain activity patterns and eventually enhance memory function, which has potential to enhance the efficacy of brain stimulation treatments for a range of cognitive disorders.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Nearly one-third of hospitalized COVID patients develop brain malfunction, study findson October 6, 2020 at 5:49 pm
Almost one-third of the patients hospitalized with COVID-19 developed encephalopathy – a degeneration of brain function – according to a study by Northwestern Medicine in Chicago.
- Brain Tumor Diagnosis and Treatments Market 2020 Global Leading Companies Analysis, Revenue, Trends and Forecasts 2026on October 6, 2020 at 10:40 am
New Study Reports “Brain Tumor Diagnosis and Treatments Market 2020 Global Market Opportunities, Challenges, Strategies and Forecasts 2026” has been Added on WiseGuyReports. This report provides in ...
- What Brain-Computer Interfaces Could Mean for the Future of Workon October 6, 2020 at 7:03 am
In the future, are we going to need BCIs to participate in business events? Beyond the analysis of brain signals, some companies are already working on solutions that can actually modulate your ...
- ANALYSIS-NextEra's Duke Energy bid faces plethora of regulatory hurdleson October 6, 2020 at 5:00 am
NextEra Energy Inc NEE.N Chief Executive James Robo joked last week he does not pursue small acquisitions because the reward is not worth the "brain damage" of getting them past regulators. Yet his ...
- Wireless Brain Sensors Market Size Worth $743.3 Million By 2027: Grand View Research, Inc.on October 6, 2020 at 1:05 am
The global wireless brain sensors market size is expected to reach USD 743.3 million by 2027, expanding at a CAGR of 9.5%, according to a ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- SMART researchers receive Intra-CREATE grant for personalized medicine and cell therapyon October 1, 2020 at 12:05 pm
MIT Alliance for Research and Technology have been awarded Intra-CREATE grants to help support research on retinal biometrics for glaucoma progression and neural cell implantation therapy for spinal ...
- Orgenesis to acquire regenerative medicine company, Koligo Therapeuticson September 30, 2020 at 2:00 am
Orgenesis Inc.(Orgenesis), a global biotech company working to unlock the full potential of cell and gene therapies, and Koligo Therapeutics, Inc. (Koligo), a regenerative medicine company, announced ...
- Orgenesis in deal to acquire regenerative medicine company Koligo Therapeuticson September 29, 2020 at 6:28 am
The agreed consideration terms include $15 million in shares of Orgenesis stock valued at $7 share which will be issued to Koligo’s accredited investors ...
- Orgenesis Announces Agreement to Acquire Koligo Therapeutics, a Leader in Personalized Cell Therapieson September 29, 2020 at 4:03 am
Acquisition to support accelerated commercialization of Koligo's KYSLECEL®, a personalized islet cell therapy available in the U.S. for chronic and recurrent acute ...
- Stem cell therapy repairs Parkinson’s degeneration in miceon September 27, 2020 at 5:00 pm
Transplanting dopaminergic neurons grown from stem cells into the brains of a Parkinson's mouse model improved motor skills.